Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SENS 
Senseonics Holdings Inc (SENS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SENS (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.43
1 Year Target Price $1.43
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.73% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 378.99M USD | Price to earnings Ratio - | 1Y Target Price 1.43 |
Price to earnings Ratio - | 1Y Target Price 1.43 | ||
Volume (30-day avg) 4 | Beta 0.89 | 52 Weeks Range 0.25 - 1.40 | Updated Date 08/29/2025 |
52 Weeks Range 0.25 - 1.40 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.02 | Actual -0.02 |
Profitability
Profit Margin -267.86% | Operating Margin (TTM) -215.42% |
Management Effectiveness
Return on Assets (TTM) -31% | Return on Equity (TTM) -102.61% |
Valuation
Trailing PE - | Forward PE 21.51 | Enterprise Value 289581218 | Price to Sales(TTM) 14.88 |
Enterprise Value 289581218 | Price to Sales(TTM) 14.88 | ||
Enterprise Value to Revenue 11.37 | Enterprise Value to EBITDA 1.76 | Shares Outstanding 814681024 | Shares Floating 740487920 |
Shares Outstanding 814681024 | Shares Floating 740487920 | ||
Percent Insiders 9.02 | Percent Institutions 18.58 |
Upturn AI SWOT
Senseonics Holdings Inc
Company Overview
History and Background
Senseonics Holdings Inc. was founded in 1996. The company focuses on developing and manufacturing continuous glucose monitoring (CGM) systems for people with diabetes. Their main product is the Eversense CGM system.
Core Business Areas
- Continuous Glucose Monitoring (CGM) Systems: Senseonics develops and commercializes long-term implantable CGM systems. Their primary product is the Eversense CGM, which is implanted under the skin and provides continuous glucose readings to a mobile app.
Leadership and Structure
The leadership team includes Rick Legari (President and CEO). The company operates with a structure typical of a medical device company, focusing on R&D, manufacturing, commercialization, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Eversense CGM System: The Eversense CGM system is Senseonics' flagship product. It's a long-term implantable CGM system that provides glucose readings for up to six months. The company is currently working towards 1-year implantable sensor. Market share information isn't readily available, but Senseonics is a smaller player compared to Abbott and Dexcom. Competitors include Abbott (FreeStyle Libre), Dexcom (G6, G7), and Medtronic.
Market Dynamics
Industry Overview
The CGM market is growing rapidly, driven by the increasing prevalence of diabetes and the benefits of continuous glucose monitoring. The industry is competitive, with major players like Abbott and Dexcom dominating the market.
Positioning
Senseonics differentiates itself with its long-term implantable sensor, offering a unique value proposition compared to traditional CGM systems. Their competitive advantages are the reduced frequency of sensor replacements and the potential for improved user adherence.
Total Addressable Market (TAM)
The global CGM market is projected to reach tens of billions of dollars. Senseonics is positioned to capture a portion of this TAM with its long-term implantable technology, specifically targeting patients seeking convenience and reduced maintenance.
Upturn SWOT Analysis
Strengths
- Long-term implantable sensor
- Potential for improved patient adherence
- Reduced frequency of sensor replacements
- Partnerships with Ascensia Diabetes Care
- FDA approval for product offerings
Weaknesses
- High initial cost of implantation
- Reliance on partnerships for commercialization
- Smaller market share compared to competitors
- Surgical procedure required for insertion and removal
Opportunities
- Expanding partnerships with healthcare providers
- Development of next-generation CGM systems
- Increasing adoption of CGM technology
- Growth in the diabetes patient population
- Penetration into new geographic markets
Threats
- Competition from established CGM players
- Technological advancements by competitors
- Reimbursement challenges from payers
- Regulatory hurdles for new products
- Potential complications from sensor implantation
Competitors and Market Share
Key Competitors
- DEX
- ABT
- MDT
Competitive Landscape
Senseonics' implantable technology differentiates it, but it faces strong competition from established players. Its success depends on demonstrating the clinical and economic benefits of its unique product.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been marked by periods of rapid expansion in revenue, followed by declines, associated with regulatory approvals and commercialization.
Future Projections: Future growth is projected to depend on the expansion of its partnerships, further market penetration, and regulatory approval of new technologies.
Recent Initiatives: Recent initiatives include partnerships with Ascensia Diabetes Care to distribute and market Eversense, and ongoing R&D efforts to improve sensor accuracy and longevity.
Summary
Senseonics offers a unique long-term implantable CGM with the potential to improve patient adherence. However, the company faces significant competition, relies on partnerships for commercialization, and needs to demonstrate sustainable revenue growth and move towards profitability. Further market penetration and successful new product development are crucial for its long-term success. Reimbursement challenges and technological competition also pose potential headwinds.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Senseonics Holdings Inc
Exchange NYSE MKT | Headquaters Germantown, MD, United States | ||
IPO Launch date 2016-03-17 | President, CEO & Director Dr. Timothy T. Goodnow Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 117 | Website https://www.senseonics.com |
Full time employees 117 | Website https://www.senseonics.com | ||
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.